Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
Dateline City:
MADISON, N.J. First Vaccine to Offer Protection Against Both Strains of Canine InfluenzaMADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United
States and Canada, today announced that the U.S. Department of
Agriculture has approved a license for Nobivac® Canine Flu
Bivalent vaccine – the first vaccine to aid in the control of disease
associated with both canine influenza virus (CIV) H3N2 and canine
influenza virus H3N8.Language:
EnglishContact: MerckMedia:Kelly Goss, 913-558-6452kelly.goss@merck.comorPamela E...
Source: Merck.com - Corporate News - October 7, 2016 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK Merck Animal Health Nobivac NYSE:MRK Source Type: news
Merck to Present New Data on ZEPATIER ™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that new data from the company ’s chronic hepatitis C
virus (HCV) clinical development programs will be presented atThe
Liver Meeting® 2016. Fifteen scientific abstracts,
including seven oral and eight poster presentations, will highlight
findings from Merck ’s HCV clinical development programs.Language:
EnglishContact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy ...
Source: Merck.com - Corporate News - October 3, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news
Merck Foundation Grant Expands YMCA ’s Diabetes Prevention Program in Five States
Dateline City:
KENILWORTH, N.J. $2 Million Grant Boosts Efforts to Prevent Type 2 Diabetes in Participants with PrediabetesKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation and YMCA of the USA (Y-USA) announced today that
the Merck Foundation has provided a grant of $2 million over three years
to support efforts to expand the YMCA ’s Diabetes Prevention Program
(YMCA’s DPP). This evidence-based, chronic disease prevention program
aims to improve the health of participants with prediabetes through
modest weight loss achieved by healthy eating and physical activity.Language:
...
Source: Merck.com - Corporate News - September 29, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
Two New Trials of Merck ’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016
Dateline City:
KENILWORTH, N.J. Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented Comprehensive Data from Merck ’s Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that extensiv...
Source: Merck.com - Corporate News - September 28, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its third-quarter 2016 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct.
25. During the call, company executives will provide an overview of
Merck ’s performance for the quarter.Language:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - September 23, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will host a teleconference for investors following the presentation of
data at the European Society for Medical Oncology (ESMO) 2016 Congress
in Copenhagen, Denmark, Oct. 7 – 11. The call will take place on Sunday,
Oct. 9 at 6:30 p.m. CEST (12:30 p.m. EDT). Company executives will
provide an overview of data presented and address questions.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Te...
Source: Merck.com - Corporate News - September 20, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK ESMO MSD Source Type: news
Merck Publishes 2015/2016 Global Corporate Responsibility Report
Dateline City:
KENILWORTH, N.J. Report Highlights Company ’s Long-Standing Commitment to Discovering Innovative and Sustainable Solutions to the World’s Greatest Health and Development ChallengesKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today issued its2015/2016
global corporate responsibility report. The report reflects the
company ’s performance in the areas of Access to Health, Environmental
Sustainability, Employees and Ethics& Transparency.Language:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036o...
Source: Merck.com - Corporate News - September 13, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, chairman and chief executive
officer, and Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, are scheduled to participate at the Morgan Stanley Global
Healthcare Conference in New York on Sept. 12, 2016 at 1:05 p.m. EDT.Language:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: ...
Source: Merck.com - Corporate News - September 9, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Morgan Stanley Global Healthcare Conference NYSE:MRK Source Type: news
Merck ’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Dateline City:
KENILWORTH, N.J. Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated PatientsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission (EC) has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, at a dose of 2 mg/kg
every three weeks, for patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) in patients whose tumors express
PD-L1 and who have received at least one prior ...
Source: Merck.com - Corporate News - August 2, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
Merck Announces Second-Quarter 2016 Financial Results
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < ul > < li > Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign ...
Source: Merck.com - Corporate News - July 29, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
Merck Announces Fourth-Quarter 2016 Dividend
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.46 per share of the company ’s common stock for the fourth
...
Source: Merck.com - Corporate News - July 26, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Dividend MSD Source Type: news
Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced two regulatory milestones for the company ’s
investigational vaccine for Ebola Zaire, V920 (rVSV∆G-ZEBOV-GP, live
attenu...
Source: Merck.com - Corporate News - July 25, 2016 Category: Pharmaceuticals Tags: Ebola Newsroom Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
Merck Animal Health Receives FDA Approval of BRAVECTO ® (fluralaner topical solution) for Cats and Dogs
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
MADISON, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks < /p > < /div > < /div > < /div > < p > MADISON, N.J.--( < a target= " _blank " href= ...
Source: Merck.com - Corporate News - July 21, 2016 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK Bravecto Merck Animal Health MSD Source Type: news
Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today said that the U.S. Food and Drug Administration (FDA) has
requested the submission of new data and analyses from the MODIFY I and
MOD...
Source: Merck.com - Corporate News - July 21, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Bezlotoxumab MSD NYSE:MRK Source Type: news
Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.
Dateline City:
MADISON, N.J.
Manufacturer Offers Substantial Portfolio of Animal Vaccines in Latin America
MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United
States and Canada) today announced it has executed an agreement to
acquire a controlling interest in Vallée S.A., a leading privately-held
producer of animal health products in Brazil.
Language:
English
...
Source: Merck.com - Corporate News - July 1, 2016 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK Vallee Source Type: news
